company background image
CADL logo

Candel Therapeutics NasdaqGM:CADL Stock Report

Last Price

US$1.54

Market Cap

US$44.5m

7D

2.7%

1Y

9.2%

Updated

27 Mar, 2024

Data

Company Financials +

Candel Therapeutics, Inc.

NasdaqGM:CADL Stock Report

Market Cap: US$44.5m

CADL Stock Overview

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.

CADL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Candel Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Candel Therapeutics
Historical stock prices
Current Share PriceUS$1.54
52 Week HighUS$1.95
52 Week LowUS$0.66
Beta0.96
1 Month Change-13.48%
3 Month Change10.79%
1 Year Change9.17%
3 Year Changen/a
5 Year Changen/a
Change since IPO-78.00%

Recent News & Updates

Recent updates

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Candel Therapeutics appoints CFO, chief medical officer

Sep 07

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Oct 21

Shareholder Returns

CADLUS BiotechsUS Market
7D2.7%0.9%0.4%
1Y9.2%10.3%28.8%

Return vs Industry: CADL matched the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: CADL underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is CADL's price volatile compared to industry and market?
CADL volatility
CADL Average Weekly Movement12.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CADL's share price has been volatile over the past 3 months.

Volatility Over Time: CADL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200376Paul-Peter Takhttps://www.candeltx.com

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.

Candel Therapeutics, Inc. Fundamentals Summary

How do Candel Therapeutics's earnings and revenue compare to its market cap?
CADL fundamental statistics
Market capUS$44.54m
Earnings (TTM)-US$31.93m
Revenue (TTM)US$31.00k

1,437x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CADL income statement (TTM)
RevenueUS$31.00k
Cost of RevenueUS$21.56m
Gross Profit-US$21.53m
Other ExpensesUS$10.40m
Earnings-US$31.93m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.10
Gross Margin-69,438.71%
Net Profit Margin-102,990.32%
Debt/Equity Ratio91.9%

How did CADL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.